KOPRAN
Pharmaceuticals & Drugs
₹223.35
0.00 (0.00%)
| Market Cap | 1,076 Cr | EPS | 4.6 | High | 225.95 | ||
| Stock P/E | 48.0 | Net Profit Margin | 4.0 | Low | 221.45 |
Performance
Today’s Low
Today’s High
221.45
225.95
52W Low
52W High
96
253
| Open Price | 224.05 | Volume | 1 |
| Prev. Close | 226.3 |
Fundamentals
| Market Cap | 1,076 Cr | ROE | 18.2% | ||
| P/E Ratio(TTM) | 48.0 | EPS(TTM) | 0.0 | ||
| P/B Ratio | 2.4 | Dividend Yield | 1.3% | ||
| Industry P/E | 41.8 | Book Value | 91.7 | ||
| Face Value | 10.0 |
About the Company
The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.
Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.
Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.
Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.
The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.
KRLL is a 100% subsidiary of Kopran Ltd. KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.
Product range of the company includes:
Finished Dosage Forms
- Antibiotics/antibacterials
- Anti-malarial
- Cadiovasculars
- Pain management
- Anthelminthics
- Antiprotozoals
- Antidiabetics
- Gastrointestinals
- Drug for erectile dysfuntion
- Antiallergics
- Respiratory/anti-asthmatics
- Metered dose inhalers
- Dry powder inhalers
- Antiviral
Active Pharmaceutical Ingredients
- Anti-hypertensives
- Macrolides
- Taste Masked
- Cephalosporins
- Under Development
- Others
Achievements/ recognition:
- Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline
Future plans:
- Brand Equity Development
- Research for New Chemical Entities
- Globalise its operations thus making Kopran a truly International Pharmaceutical Company.
| Parent Organization | Kopran Ltd. | Managing Director | |||
| Founded | 1958 | NSE Symbol | KOPRAN |
Financials
All values are in Rs Cr
Shareholding Pattern
Domestic Institutions
0.13%
Foreign Institutions
0.50%
Mutual Funds
0.00%
Promoters
44.25%
Domestic Institutions
0.13%
Foreign Institutions
0.50%
Mutual Funds
0.00%
Promoters
44.25%
Domestic Institutions
0.13%
Foreign Institutions
0.50%
Mutual Funds
0.00%
Promoters
44.25%
Domestic Institutions
0.13%
Foreign Institutions
0.50%
Mutual Funds
0.00%
Promoters
44.25%
Domestic Institutions
0.13%
Foreign Institutions
0.50%
Mutual Funds
0.00%
Promoters
44.25%
Peer Comparison
| Company | 52 Week | Market Price | P/E Ratio | Financials | Share Holding |
|---|---|---|---|---|---|
223.35(-1.3%) | 48.0 | ||||
412.3(-0.3%) | 34.5 | ||||
122.75(1.2%) | 60.2 | ||||
391.55(-0.5%) | 0.0 |
